Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world’s second-largest economy, where the appetite for similar treatments is surging.
Related Posts
European IPO Revival Still Lags Behind U.S.
Europe’s market for initial public offerings got off to a lively start in the fourth quarter, winding down a better year for new listings, though […]
China EV Sales Rallied in June on Policy, Price Cuts
Chinese electric vehicle makers had robust sales in June, helped by government subsidies, tax breaks and steep discounts that brought buyers back into showrooms after […]
Basic Materials Roundup: Market Talk
- staff
- January 22, 2025
- 0
Find insight on BHP, Lanxess, Evolution and more in the latest Market Talks covering Basic Materials.